TRVI Company Profile and Key Details
Trevi Therapeutics, Inc.
TRVI Stock Price Chart
Stock Price Today
Trevi Therapeutics, Inc. (TRVI) stock declined over -3.32%, trading at $4.08 on NASDAQ, down from the previous close of $4.22. The stock opened at $4.22, fluctuating between $4.02 and $4.27 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Company Information
| Employees | 27 |
| Beta | 1.01 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Trevi Therapeutics, Inc. (NASDAQ: TRVI) stock price is $4.08 in the last trading session. During the trading session, TRVI stock reached the peak price of $4.27 while $4.02 was the lowest point it dropped to. The percentage change in TRVI stock occurred in the recent session was -3.32% while the dollar amount for the price change in TRVI stock was -$0.14.
The NASDAQ listed TRVI is part of Biotechnology industry that operates in the broader Healthcare sector. Trevi Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. Christopher Galletta
Controller & Chief Accounting Officer
Ms. Jennifer L. Good
Co-Founder, Chief Executive Officer, Pres & Director
Dr. Thomas R. Sciascia M.D.
Co-Founder & Chief Science Officer
Ms. Danine Summers
Vice President of Medical Affairs
Katie McManus
Communications Mang.
Mr. Farrell Simon Pharm.D.
Chief Commercial Officer
Dr. David J. Clark A.F.P.M., M.D., M.R.C.P.
Chief Medical Officer
Ms. Lisa Delfini
Chief Financial Officer
TRVI's closing price is 193.53% higher than its 52-week low of $1.39 where as its distance from 52-week high of $4.68 is -12.82%.
Number of TRVI employees currently stands at 27.
Official Website of TRVI is: https://www.trevitherapeutics.com
TRVI could be contacted at phone 203 304 2499 and can also be accessed through its website. TRVI operates from 195 Church Street, New Haven, CT 06510, United States.
TRVI stock volume for the day was 312.47K shares. The average number of TRVI shares traded daily for last 3 months was 1.77M.
The market value of TRVI currently stands at $364.61M with its latest stock price at $4.08 and 89.37M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com